Sponsors (19)
The bill expands access to WGS/WES for Medicaid-enrolled children—potentially improving diagnoses and outcomes—while increasing Medicaid costs and creating implementation and reimbursement risks that states, providers, and taxpayers must manage.
Medicaid-enrolled children and youth with suspected genetic disorders will gain coverage of whole genome/whole exome sequencing (WGS/WES) as a covered medical service, improving access to diagnostic testing and earlier diagnosis.
Hospitals, labs, and Medicaid beneficiaries will see sequencing paid as a separate line item rather than bundled, which should improve provider reimbursement transparency and encourage more labs/providers to offer testing to Medicaid patients.
State governments, providers, and families will benefit from HHS outreach, stakeholder convenings, and a GAO assessment that aim to identify implementation barriers (e.g., prior authorization, workforce) and recommend improvements within two years.
Taxpayers and state governments will face increased Medicaid spending due to expanded coverage of sequencing, which could pressure state budgets or require additional federal/state funding adjustments.
Hospitals, labs, and patients could still experience limited access if provider payment rates are set too low or misaligned with market costs, resulting in inadequate reimbursement and reduced provider participation despite the coverage mandate.
Medicaid beneficiaries and state Medicaid programs face a risk of overuse if sequencing is treated as a 'first-tier' test in some cases without well-defined clinical criteria or robust prior authorization safeguards.
Based on analysis of 2 sections of legislative text.
Requires Medicaid to cover whole genome and whole exome sequencing (with analysis and reporting) as separate reimbursable medical assistance for children suspected of genetic or rare conditions.
Introduced January 15, 2026 by Scott Peters · Last progress January 15, 2026
Requires Medicaid to cover whole genome sequencing (WGS) and whole exome sequencing (WES) — including associated analysis and clinical reporting — as medical assistance when ordered as a first-line test for children suspected of having a genetic disorder, rare disease, or an unexplained condition such as congenital anomalies, global developmental delay, or intellectual disability. It defines sequencing services, requires states to make separate (non-bundled) payments for these tests, directs federal outreach and data collection, and mandates HHS and GAO reports on payment, utilization, workforce, prior authorization, and cost alignment; the changes take effect January 1, 2027. The law also directs HHS to convene stakeholders and do outreach to states, and directs GAO to assess implementation impacts and make recommendations within two years of enactment.